The FDA still hates low T drugs — ex­perts bat back a pair of con­tenders

The FDA isn’t re­lent­ing on its skep­ti­cal at­ti­tude to­ward new testos­terone ther­a­pies. And nei­ther are the ex­perts that ad­vise the agency on new drug ap­pli­ca­tions in the field.

Lipocine is the lat­est biotech to feel the whip as an FDA ad­vi­so­ry pan­el vot­ed 13 to 6 against rec­om­mend­ing an ap­proval for Tlando, an oral drug that was de­signed to re­place the gels that have been avail­able. And its shares $LPCN cratered on the shutout, drop­ping 58% af­ter the vote came down.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER